A Phase 1 interventional study of Seladelpar in Primary Biliary Cholangitis, Compensated Cirrhosis and Hepatic Impairment, sponsored by Gilead Sciences. Completed at 20 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 1, and was the 7th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Gilead Sciences · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 126 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Participants with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Screening laboratory parameters:
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with primary biliary cholangitis (PBC) and a Child-Pugh (CP) classification of CP-A (score 5 to 6) without portal hypertension (PHT) will receive a single dose of seladelpar 10 mg, orally, on Day 1.
Drug: Seladelpar
Participants with PBC and a CP classification of CP-A (score 5 to 6) with PHT will receive a single dose of seladelpar 10 mg, orally, on Day 1.
Drug: Seladelpar
Participants with PBC and a CP classification of CP-B (score 7 to 9) will receive a single dose of seladelpar 10 mg, orally, on Day 1.
Drug: Seladelpar
Participants with PBC and a CP classification of CP-C (score 10 to 12) will receive a single dose of seladelpar 10 mg, orally, on Day 1.
Drug: Seladelpar
Participants with PBC and a CP classification of CP-A (score 5 to 6) with PHT, who complete Part A, will receive seladelpar 10 mg or 5 mg, orally, once daily, for 28 days. Doses for Part B will be chosen based on exposure from a single dose in Part A for individual participants.
Drug: Seladelpar
Participants with PBC and a CP classification of CP-B (score 7 to 9), who complete Part A, will receive seladelpar 10 mg or 5 mg, orally, once daily, for 28 days. Doses for Part B will be chosen based on exposure from a single dose in Part A for individual participants.
Drug: Seladelpar
Tablets Administered Orally
Also known as: Livdelzi®
Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)
Cmax is defined as the maximum observed plasma concentration of the study drug.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)
Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
AUC0-t is defined as area under the concentration--time curve from time zero to the last measurable concentration.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)
AUC0-inf is defined as area under the concentration--time curve from time zero extrapolated to infinity, calculated as AUC0-t+Ct/Kel, where: Ct = the last measurable concentration and Kel = elimination rate constant.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)
Cmax is defined as the maximum observed plasma concentration of the study drug.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)
Cmax,ss is defined as the steady-state maximum observed plasma concentration of the study drug at Day 28.
Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)
Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)
Tmax,ss is defined as the steady-state time to reach maximum observed plasma concentration of the study drug at Day 28.
Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)
AUC0-24 is defined as area under the concentration-time curve from time zero to 24 hours.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)
AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.
Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)
RCmax is defined as the accumulation ratio based on Cmax, calculated as Cmax on Day 28/ Day 1.
Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
RAUC0-t is defined as the accumulation ratio based on AUC0-t, calculated as AUC0-tau on Day 28/ AUC0-24 on Day 1 for participants with dose once a day.
Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs
An adverse event (AE) was defined as any medical occurrence in a participant administered to a pharmaceutical product in a clinical study, regardless of a causal relationship with this treatment. TEAEs were defined as AEs that commenced or worsened on or after the time of study drug administration in Part A until up to 30 days after study drug administration in Part A or before the first study drug administration in Part B (whichever is earlier). For Part B, TEAEs are defined as AEs that commence or worsen on or after the time of first study drug administration in Part B until up to 30 days after the last study drug administration in Part B. A drug-related TEAE was defined as TEAE which was related (reported as 'possible', 'probable', or 'definite') to study drug. Percentages were rounded off.
Time frame: Part A: Up to Week 5; Part B: Up to Week 8
Percentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEs
TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced. The percentage of participants with any severity grade and severity grade of 3 or 4 were reported. Percentages were rounded off.
Time frame: Part A: Up to Week 5; Part B: Up to Week 8
Percentage of Participants Who Experienced TEAEs of Special Interest
TEAEs of special interest for this study were defined as AEs that met CTCAE version 5.0 or the most recent version Grade 2 criteria or higher for AEs of elevated alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine kinase, lipase, or serum creatinine. Hepatic decompensation clinical events including ascites, jaundice, esophageal variceal bleeding, and hepatic encephalopathy, were also defined as TEAEs of special interest for this study. Percentages were rounded off.
Time frame: Part A: Up to Week 5; Part B: Up to Week 8
Percentage of Participants With Clinically Significant Changes in Vital Signs
Vital signs (including oral temperature, respiratory rate, seated blood pressure \[diastolic and systolic\], and heart rate) were evaluated. Percentage of participants with clinically significant changes in vital signs evaluations was reported. The clinically significant changes were based on investigator's judgement.
Time frame: Part A: Up to Day 4; Part B: Up to Day 31
Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings
ECG measurements included the parameters of heart rate, ventricular rate, PR interval, QRS duration, QT interval (uncorrected), and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Per protocol, ECG findings were classified in 1 of 3 categories: normal, abnormal but not clinically significant, or abnormal and clinically significant. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.
Time frame: Part A: Up to Day 4; Part B: Up to Day 28
Percentage of Participants Who Experienced Laboratory Abnormalities
Clinical laboratory parameters included biochemistry, hematology, coagulation, and urinalysis. Abnormal laboratory values were graded according to the NCI CTCAE version 5.0.Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. The percentage of participants with a shift of ≥ 2 NCI CTCAE grade from baseline was reported.
Time frame: Part A: Up to Day 4; Part B: Up to Day 31
Part A: PK Parameter (Urine): Ae0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
Ae0-t is defined as the cumulative urinary excretion from time zero to time t, calculated as the sum of the amounts excreted over each collection interval.
Time frame: Day 1: Predose; 0-6 h, and 6-12 h postdose
Part A: PK Parameter (Urine): CLR of Seladelpar
CLR is defined as the renal clearance, calculated as Ae0-t / AUC0-12.
Time frame: Day 1: Predose; 0-6 h, and 6-12 h postdose
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Prothrombin Time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Prothrombin Time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Prothrombin Time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar Cmax and CP Score
Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score
Rsq is defined as the R-squared value for the regression between AUC0-inf and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part A: Rsq Between Plasma Seladelpar AUC0-t and CP Score
Rsq is defined as the R-squared value for the regression between AUC0-t and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin
Rsq is defined as the R-squared value for the regression between Cmax and baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline Albumin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between Cmax and baseline prothrombin time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline prothrombin time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline prothrombin time.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between Cmax and baseline bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline bilirubin.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar Cmax and CP Score
Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-t and CP Score
Rsq is defined as the R-squared value for the regression between AUC0-t and and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Part B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score
Rsq is defined as the R-squared value for the regression between AUC0-inf and and CP score of participants.
Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Participants were enrolled at study sites in the United States, South Korea, Spain, and the United Kingdom.
| Milestone | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 5 |
| Completed | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cmax is defined as the maximum observed plasma concentration of the study drug.
| nanograms per milliliter (ng/mL) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| Cmax of Seladelpar | 182.0 ± 60.68 | 367.7 ± 238.28 | 359.2 ± 158.61 | 388.5 ± 153.45 |
| Cmax of M1 | 20.08 ± 9.012 | 33.17 ± 9.913 | 47.27 ± 22.439 | 40.07 ± 12.974 |
| Cmax of M2 | 225.3 ± 117.66 | 257.7 ± 30.58 | 291.7 ± 92.68 | 217.7 ± 36.58 |
| Cmax of M3 | 42.55 ± 20.510 | 28.78 ± 6.739 | 34.50 ± 10.994 | 23.88 ± 9.182 |
Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.
| hours (h) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| Tmax of Seladelpar | 1.208 (0.500 to 2.500) | 0.758 (0.500 to 6.000) | 1.250 (0.417 to 3.000) | 1.250 (0.500 to 2.500) |
| Tmax of M1 | 4.000 (2.417 to 8.000) | 4.500 (2.017 to 6.000) | 3.000 (0.417 to 6.000) | 5.000 (2.517 to 6.000) |
| Tmax of M2 | 5.500 (2.500 to 8.117) | 4.000 (2.017 to 8.000) | 4.000 (2.917 to 6.033) | 8.000 (2.517 to 12.100) |
| Tmax of M3 | 5.500 (4.017 to 12.083) | 4.500 (2.983 to 8.000) | 4.500 (2.917 to 6.033) | 6.000 (3.017 to 24.000) |
AUC0-t is defined as area under the concentration--time curve from time zero to the last measurable concentration.
| h*ng/mL | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| AUC0-t of Seladelpar | 800 ± 214 | 1390 ± 504 | 1390 ± 812 | 1970 ± 416 |
| AUC0-t of M1 | 239 ± 41.3 | 324 ± 117 | 351 ± 151 | 499 ± 287 |
| AUC0-t of M2 | 2930 ± 1140 | 3730 ± 1570 | 4550 ± 3070 | 4970 ± 1950 |
| AUC0-t of M3 | 475 ± 106 | 367 ± 143 | 394 ± 75.8 | 368 ± 171 |
AUC0-inf is defined as area under the concentration--time curve from time zero extrapolated to infinity, calculated as AUC0-t+Ct/Kel, where: Ct = the last measurable concentration and Kel = elimination rate constant.
| h*ng/mL | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| AUC0-inf of Seladelpar | 841 ± 228 | 1540 ± 474 | 1440 ± 829 | 2020 ± 443 |
| AUC0-inf of M1 | 272 ± 44.4 | 339 ± 122 | 375 ± 147 | 530 ± 284 |
| AUC0-inf of M2 | 3140 ± 1110 | 3930 ± 1620 | 4660 ± 3090 | 5270 ± 2100 |
| AUC0-inf of M3 | 580 ± 63.8 | 416 ± 156 | 495 ± 129 | 404 ± 99.2 |
Cmax is defined as the maximum observed plasma concentration of the study drug.
| ng/mL | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| Cmax of Seladelpar | 299.08 ± 182.985 | 344.40 ± 121.049 | 78.40 ± NA | 229.00 ± NA |
| Cmax of M1 | 33.00 ± 20.903 | 57.18 ± 28.656 | 11.30 ± NA | 18.20 ± NA |
| Cmax of M2 | 268.80 ± 138.124 | 255.80 ± 40.586 | 98.60 ± NA | 181.00 ± NA |
| Cmax of M3 | 24.700 ± 7.196 | 37.860 ± 7.812 | 7.730 ± NA | 8.330 ± NA |
Cmax,ss is defined as the steady-state maximum observed plasma concentration of the study drug at Day 28.
| ng/mL | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| Cmax,ss of Seladelpar | 260.60 ± 75.255 | 324.00 ± 153.498 | 53.20 ± NA | 255.00 ± NA |
| Cmax,ss of M1 | 36.320 ± 14.365 | 44.700 ± 21.134 | 8.190 ± NA | 32.700 ± NA |
| Cmax,ss of M2 | 326.2 ± 124.20 | 297.2 ± 72.77 | 108.0 ± NA | 369.0 ± NA |
| Cmax,ss of M3 | 36.140 ± 15.451 | 48.880 ± 18.311 | 8.540 ± NA | 18.300 ± NA |
Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.
| h | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| Tmax of Seladelpar | 1.000 (1.000 to 5.000) | 1.000 (0.467 to 2.483) | 1.500 (1.500 to 1.500) | 0.500 (0.500 to 0.500) |
| Tmax of M1 | 5.983 (2.500 to 8.000) | 2.000 (0.467 to 6.000) | 8.000 (8.000 to 8.000) | 2.033 (2.033 to 2.033) |
| Tmax of M2 | 5.983 (4.000 to 8.000) | 3.500 (2.983 to 6.000) | 8.000 (8.000 to 8.000) | 6.000 (6.000 to 6.000) |
| Tmax of M3 | 6.000 (3.533 to 8.000) | 3.500 (3.000 to 6.000) | 12.000 (12.000 to 12.000) | 6.000 (6.000 to 6.000) |
Tmax,ss is defined as the steady-state time to reach maximum observed plasma concentration of the study drug at Day 28.
| h | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| Tmax,ss of Seladelpar | 1.000 (0.500 to 2.000) | 0.566 (0.500 to 1.500) | 3.500 (3.500 to 3.500) | 1.033 (1.033 to 1.033) |
| Tmax,ss of M1 | 6.000 (2.500 to 8.000) | 3.016 (1.000 to 4.000) | 5.000 (5.000 to 5.000) | 6.000 (6.000 to 6.000) |
| Tmax,ss of M2 | 6.000 (2.500 to 8.000) | 3.500 (2.500 to 5.900) | 12.000 (12.000 to 12.000) | 6.000 (6.000 to 6.000) |
| Tmax,ss of M3 | 5.000 (4.000 to 8.000) | 4.000 (2.500 to 6.000) | 12.000 (12.000 to 12.000) | 7.917 (7.917 to 7.917) |
AUC0-24 is defined as area under the concentration-time curve from time zero to 24 hours.
| h*ng/mL | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| AUC0-24 of Seladelpar | 1450 ± 548 | 1053 ± 191 | 814 ± NA | 1494 ± NA |
| AUC0-24 of M1 | 346 ± 183 | 338 ± 59 | 167 ± NA | 209 ± NA |
| AUC0-24 of M2 | 3812 ± 2315 | 2892 ± 649 | 1837 ± NA | 3219 ± NA |
| AUC0-24 of M3 | 354 ± 134 | 449 ± 85 | 141 ± NA | 150 ± NA |
AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.
| h*ng/mL | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| AUC0-tau of Seladelpar | 1329 ± 517 | 1055 ± 380 | 570 ± NA | 1680 ± NA |
| AUC0-tau of M1 | 395 ± 270 | 339 ± 121 | 136 ± NA | 359 ± NA |
| AUC0-tau of M2 | 4377 ± 2860 | 3349 ± 1532 | 2161 ± NA | 6415 ± NA |
| AUC0-tau of M3 | 461 ± 308 | 521 ± 175 | 178 ± NA | 307 ± NA |
RCmax is defined as the accumulation ratio based on Cmax, calculated as Cmax on Day 28/ Day 1.
| accumulation ratio of Cmax | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| RCmax of Seladelpar | 1.121 ± 0.657 | 0.940 ± 0.300 | 0.679 ± NA | 1.114 ± NA |
| RCmax of M1 | 1.429 ± 1.056 | 0.906 ± 0.384 | 0.725 ± NA | 1.797 ± NA |
| RCmax of M2 | 1.305 ± 0.332 | 1.158 ± 0.197 | 1.095 ± NA | 2.039 ± NA |
| RCmax of M3 | 1.445 ± 0.274 | 1.264 ± 0.249 | 1.105 ± NA | 2.197 ± NA |
RAUC0-t is defined as the accumulation ratio based on AUC0-t, calculated as AUC0-tau on Day 28/ AUC0-24 on Day 1 for participants with dose once a day.
| accumulation ratio of AUC0-t | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) |
|---|---|---|---|---|
| RAUC0-t of Seladelpar | 0.957 ± 0.258 | 1.014 ± 0.275 | 0.700 ± NA | 1.124 ± NA |
| RAUC0-t of M1 | 1.130 ± 0.383 | 0.999 ± 0.286 | 0.811 ± NA | 1.720 ± NA |
| RAUC0-t of M2 | 1.222 ± 0.521 | 1.145 ± 0.392 | 1.176 ± NA | 1.993 ± NA |
| RAUC0-t of M3 | 1.253 ± 0.440 | 1.148 ± 0.296 | 1.261 ± NA | 2.055 ± NA |
An adverse event (AE) was defined as any medical occurrence in a participant administered to a pharmaceutical product in a clinical study, regardless of a causal relationship with this treatment. TEAEs were defined as AEs that commenced or worsened on or after the time of study drug administration in Part A until up to 30 days after study drug administration in Part A or before the first study drug administration in Part B (whichever is earlier). For Part B, TEAEs are defined as AEs that commence or worsen on or after the time of first study drug administration in Part B until up to 30 days after the last study drug administration in Part B. A drug-related TEAE was defined as TEAE which was related (reported as 'possible', 'probable', or 'definite') to study drug. Percentages were rounded off.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Any TEAEs | 0 | 33.3 | 16.7 | 0 | 0 | 40.0 | 0 | 60.0 |
| Study Drug-Related TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20.0 |
TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced. The percentage of participants with any severity grade and severity grade of 3 or 4 were reported. Percentages were rounded off.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Any Grade | 0 | 33.3 | 16.7 | 0 | 0 | 40.0 | 0 | 60.0 |
| Grade 3 or 4 | 0 | 0 | 0 | 0 | 0 | 20.0 | 0 | 0 |
TEAEs of special interest for this study were defined as AEs that met CTCAE version 5.0 or the most recent version Grade 2 criteria or higher for AEs of elevated alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine kinase, lipase, or serum creatinine. Hepatic decompensation clinical events including ascites, jaundice, esophageal variceal bleeding, and hepatic encephalopathy, were also defined as TEAEs of special interest for this study. Percentages were rounded off.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced TEAEs of Special Interest | 0 | 0 | 0 | 0 | 0 | 20.0 | 0 | 20.0 |
Vital signs (including oral temperature, respiratory rate, seated blood pressure \[diastolic and systolic\], and heart rate) were evaluated. Percentage of participants with clinically significant changes in vital signs evaluations was reported. The clinically significant changes were based on investigator's judgement.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECG measurements included the parameters of heart rate, ventricular rate, PR interval, QRS duration, QT interval (uncorrected), and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Per protocol, ECG findings were classified in 1 of 3 categories: normal, abnormal but not clinically significant, or abnormal and clinically significant. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical laboratory parameters included biochemistry, hematology, coagulation, and urinalysis. Abnormal laboratory values were graded according to the NCI CTCAE version 5.0.Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. The percentage of participants with a shift of ≥ 2 NCI CTCAE grade from baseline was reported.
| percentage of participants | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Laboratory Abnormalities | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 20.0 |
Ae0-t is defined as the cumulative urinary excretion from time zero to time t, calculated as the sum of the amounts excreted over each collection interval.
| ng | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| Ae0-t of Seladelpar | 1370 ± 1020 | 4660 ± 3770 | 6460 ± 5830 | 3290 ± 2940 |
| Ae0-t of M1 | 0.513 ± 0.634 | 0.957 ± 0.352 | 0.976 ± 0.675 | 0.503 ± 0.261 |
| Ae0-t of M2 | 0.119 ± 0.089 | 0.363 ± 0.462 | 0.345 ± 0.314 | 0.056 ± 0.059 |
| Ae0-t of M3 | 1.17 ± 1.01 | 2.24 ± 0.694 | 2.41 ± 1.94 | 1.04 ± 0.474 |
CLR is defined as the renal clearance, calculated as Ae0-t / AUC0-12.
| L/h | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) |
|---|---|---|---|---|
| Part A: PK Parameter (Urine): CLR of Seladelpar | 0.00208 ± 0.001520 | 0.00361 ± 0.002755 | 0.00723 ± 0.007391 | 0.00238 ± 0.002846 |
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Albumin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin | 0.2033 |
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Albumin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin | 0.3735 |
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Albumin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin | 0.3924 |
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Bilirubin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin | 0.0318 |
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Bilirubin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin | 0.1810 |
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Bilirubin.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin | 0.2047 |
Rsq is defined as the R-squared value for the regression between Cmax and Baseline Prothrombin Time.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time | 0.2774 |
Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Prothrombin Time.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time | 0.6014 |
Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Prothrombin Time.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time | 0.5804 |
Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar Cmax and CP Score | 0.1092 |
Rsq is defined as the R-squared value for the regression between AUC0-inf and CP score of participants.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score | 0.3056 |
Rsq is defined as the R-squared value for the regression between AUC0-t and CP score of participants.
| no unit | Part A: Seladelpar 10 mg |
|---|---|
| Part A: Rsq Between Plasma Seladelpar AUC0-t and CP Score | 0.3250 |
Rsq is defined as the R-squared value for the regression between Cmax and baseline Albumin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin | 0.3351 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline Albumin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Day 1 | 0.0400 | NA |
| Day 28 | 0.1175 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline Albumin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin | 0.0456 | NA |
Rsq is defined as the R-squared value for the regression between Cmax and baseline prothrombin time.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time | 0.3124 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline prothrombin time.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Day 1 | 0.1934 | NA |
| Day 28 | 0.3108 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline prothrombin time.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time | 0.2020 | NA |
Rsq is defined as the R-squared value for the regression between Cmax and baseline bilirubin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin | 0.0012 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-t and baseline bilirubin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Day 1 | 0.1136 | NA |
| Day 28 | 0.0805 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline bilirubin.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin | 0.0993 | NA |
Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar Cmax and CP Score | 0.0118 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-t and and CP score of participants.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Day 1 | 0.2036 | NA |
| Day 28 | 0.1912 | NA |
Rsq is defined as the R-squared value for the regression between AUC0-inf and and CP score of participants.
| no unit | Part B: Seladelpar 10 mg | Part B: Seladelpar 5 mg |
|---|---|---|
| Part B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score | 0.1901 | NA |
Collected over All-cause Mortality: Up to 31 weeks; Adverse Events: Part A: Up to Week 5; Part B: Up to Week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | 0/5 (0%) | 1/5 (20%) | 2/5 (40%) |
| Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B: Cohort 3 - CP-B (Seladelpar 10 mg) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Event | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Generalised oedemaGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| BronchitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| Event | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg) | Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part B: Cohort 3 - CP-B (Seladelpar 5 mg) | Part B: Cohort 3 - CP-B (Seladelpar 10 mg) |
|---|---|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| AscitesGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 0/5 | 0/1 | 1/5 |
| EructationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 0/5 | 0/1 | 1/5 |
| Ear infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| GastroenteritisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 0/5 | 0/1 | 1/5 |
| Post procedural haematomaInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/6 | 0/6 | 0/1 | 1/5 | 0/1 | 0/5 |
| Procedural painInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 0/5 | 0/1 | 1/5 |
| Blood urea increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/1 | 0/5 | 0/1 | 1/5 |
The Safety Analysis Set included all study participants who received any amount of seladelpar.
| Age, Categorical(Participants) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 5 | 4 | 4 | 19 |
| >=65 years | 0 | 1 | 2 | 2 | 5 |
| Age, Continuous(years) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| Mean | 56 ± 4.4 | 61 ± 8.0 | 57 ± 13.6 | 61 ± 7.2 | 59 ± 8.6 |
| Sex: Female, Male(Participants) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| Female | 6 | 5 | 6 | 5 | 22 |
| Male | 0 | 1 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 2 | 6 |
| Not Hispanic or Latino | 5 | 4 | 5 | 4 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 1 | 1 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 5 | 5 | 6 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) | Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) | Part A: Cohort 3 - CP-B (Seladelpar 10 mg) | Part A: Cohort 4 - CP-C (Seladelpar 10 mg) | Total |
|---|---|---|---|---|---|
| South Korea | 4 | 0 | 1 | 0 | 5 |
| United States | 2 | 6 | 4 | 5 | 17 |
| United Kingdom | 0 | 0 | 0 | 1 | 1 |
| Spain | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion and at least 6 months after the FDA and EMA approval
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Nov 2021 to primary completion in Feb 2025, 39 months.
Results were first posted in May 2026, 1 year 2 months after primary completion.
Of 15 phase 1 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seladelpar